Accumulating evidences suggest that sex affects lung development. Indeed, a higher incidence of respiratory distress syndrome is observed in male compared to female preterm neonates at comparable developmental stage and experimental studies demonstrated an androgen-related delay in male lung maturation. However, the precise mechanisms underlying these deleterious effects of androgens in lung maturation are only partially understood.
To build up a better understanding of the effect of androgens on lung development, we analyzed by microarrays the expression of genes showing a sexual difference and those modulated by androgens. Lungs of murine fetuses resulting from a timely mating window of 1 hour were studied at gestational day 17 (GD17) and GD18, corresponding to the period of surge of surfactant production. Using injections of the antiandrogen flutamide to pregnant mice, we hunted for genes in fetal lungs which are transcriptionally modulated by androgens.
Results revealed that 1844 genes were expressed with a sexual difference at GD17 and 833 at GD18. Many genes were significantly modulated by flutamide: 1597 at GD17 and 1775 at GD18. Datasets were analyzed by using in silico tools for reconstruction of cellular pathways. Between GD17 and GD18, male lungs showed an intensive transcriptional activity of proliferative pathways along with the onset of lung differentiation. Among the genes showing a sex difference or an antiandrogen modulation of their expression, we specifically identified androgen receptor interacting genes, surfactant related genes in particularly those involved in the pathway leading to phospholipid synthesis, and several genes of lung development regulator pathways. Among these latter, some genes related to Shh, FGF, TGF-beta, BMP, and Wnt signaling are modulated by sex and/or antiandrogen treatment.
Our results show clearly that there is a real delay in lung maturation between male and female in this period, the latter pursuing already lung maturation while the proper is not yet fully engaged in the differentiation processes at GD17. In addition, this study provides a list of genes which are under the control of androgens within the lung at the moment of surge of surfactant production in murine fetal lung.
Accumulating evidence suggests that sex affects lung development and physiology. Indeed, sex hormones appear to exert regulatory effects on human lung development and maturation during both fetal and neonatal periods. During the fetal period, male lung maturation is delayed compared with female and surfactant production appears earlier in female than in male fetal lungs [
Furthermore, substantial experimental data support a role for sex hormones in lung development regulation. Indeed, several genes have been shown to be expressed with a sexual dimorphism within murine fetal maturing lung [
To build up a better understanding of the biomolecular mechanisms underlying androgens effect on lung development, we investigated the expression of genes showing a sexual dimorphism and those modulated by the presence of androgens at the moment of surge of surfactant production in murine fetal lung. For achieving this goal, microarrays were performed on fetal mouse lungs of both sexes harvested at gestational day 17 (GD17) and GD18 (term is GD19), preceded by maternal daily injections of the pure antiandrogen flutamide or the vehicule solution (control) from GD10. In the mouse, GD17 and GD18 represent the transition between canalicular and saccular stages of lung development, which overlaps the surge of surfactant production. Then, the present investigation has been designed to provide valuable insights in the study of the signalling mechanisms leading to surfactant synthesis and pulmonary maturation. In general, the results show that thousands of genes are transcriptionally modulated within the developing lung in response to the fetal androgenic status. More specifically, we report the modulation of androgen receptor interacting genes, surfactant related genes and particularly those involved in the pathway leading to phospholipid synthesis, and several genes of lung development regulator pathways.
Protocols were approved by the Animal Care and Use Committee and the Institutional Review Board of the Centre de Recherche du Centre Hospitalier Universitaire de Québec (protocol no. 2005-156). BALB/c mice (
Flutamide antiandrogen (kindly provided by Dr Fernand Labrie) was dissolved in a saline vehicule solution (0.9% NaCl) containing 1% gelatin (W/V) (ACP Chemicals, Saint-Léonard, QC, Canada) and 10% dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO). Pregnant females received a daily sub-cutaneous injection of 200 μl of flutamide (1 mg) or vehicule solution from GD10 to the day prior to harvesting day. Pregnant females were sacrificed by exposure to CO2 at GD17 or GD18. From each fetus, lungs and a rear leg were harvested and rapidly frozen on dry ice and then stored at -80°C until use.
Fetal sex was identified by examination of the genital tract with a dissecting microscope at 15× magnification and confirmed by PCR amplification of the male-specific
Total RNA was extracted from fetal lung using Tri-reagent, a mixture of phenol and guanidine thiocyanate in a monophasic solution (Molecular Research Center, Cincinnati, OH) as described previously [
For each RNA pool, 20 μg of total RNA was converted to cDNA by using SuperScript II reverse transcriptase (Invitrogen), and T7-oligo-d(T)24 (Geneset) as a primer. T7 BioArray High Yield RNA Transcript Labeling Kit was used to produce biotinylated cRNA. The mixture (20 μl final volume) was incubated at 37°C for 5 h with gentle mixing every 30 min. Labelled cRNA was purified using a RNeasy Mini Kit (Qiagen) according to the protocol of the manufacturer. Purified cRNA was fragmented into segments of 20-300 nucleotide length by incubation in a fragmentation buffer (100 mM potassium acetate, 30 mM magnesium acetate, 40 mM Tris-acetate pH 8.1) for 20 min at 94°C. The quality of cRNA amplification and cRNA fragmentation was monitored by micro-capillary electrophoresis (Bioanalyser 2100, Agilent Technologies, Mississauga, ON, Canada).
Fifteen micrograms of fragmented cRNA was hybridized for 16 h at 45°C with constant rotation, using a mouse oligonucleotide array MOE430 2.0 (Genechip, Affymetrix, Santa Clara, CA). After hybridization, chips were processed by using the Affymetrix GeneChip Fluidic Station 450 (protocol EukGE-WS2v5_450). Staining was made with streptavidin-conjugated phycoerythrin (SAPE; Molecular Probes), followed by amplification with a biotinylated anti-streptavidin antibody (Vector Laboratories), and by a second round of SAPE. Chips were scanned using a GeneChip Scanner 3000 G7 (Affymetrix) enabled for High-Resolution Scanning. Images were extracted with the GeneChip Operating Software (Affymetrix GCOS v1.4). Quality control of microarray chips was performed using the AffyQCReport software [
The MOE430 2.0 microarray provides coverage of over 45,000 probe sets corresponding to about 39,000 transcripts and variants. The probe sets were selected from sequences derived from GenBank, dbEST and RefSeq. The sequence clusters were created from the UniGene database (Build 107, June 2002) and then refined by analysis and comparison with the publicly available draft assembly of the mouse genome from the Whitehead Institute Center for Genome Research (MSCG, April 2002). Data sets have been deposited in GEO (GSE18135).
The background subtraction and normalization of probe set intensities was performed using the Robust Multiarray Analysis (RMA) method described by Irizarry et al. [
Fetal lung gene expression was compared at both GD17 and GD18 between males and females (17 f
At GD17, 88% of the genes expressed with a sexual difference were more highly expressed in male lungs than in female lungs and this proportion decreased to 59% at GD18 (Fig.
Genes showing expression modulation by sex and/or antiandrogen treatment were analyzed by using the Gene Ontology website
The subset of genes presenting sex difference and being affected by flutamide at the same gestational age (590 at GD17, 428 at GD18) were regrouped in accordance with their pattern of relative pulmonary expression level among experimental groups (Table
Expression patterns of genes transcriptionally modulated by sex and antiandrogen treatment within fetal lung
| Expression pattern | Relative expression level among groups1 | Number of genes | |
|---|---|---|---|
| GD172 | GD18 | ||
| #1 | flut > m > f | 0 | 0 |
| #2 | m > flut > f | 359 | 93 |
| #3 | flut > f > m | 7 | 21 |
| #4 | f > flut > m | 12 | 63 |
| #5 | m > f > flut | 212 | 251 |
| #6 | f > m > flut | 0 | 0 |
1Groups are flutamide treated males (flut), males (m), and females (f)
2GD = Gestational day
Genes related to hormones, lipid processing, and lung function that are modulated by sex and antiandrogen treatment
|
|
|
|
|
|
|
|||
| Steroid | Hsd17b12 | Hydroxysteroid (17-beta) dehydrogenase 12 | #2 (m > flut > f) |
| Androgen | Ext1 | Exostoses (multiple) 1 | #2 (m > flut > f) |
| Glucocorticoid | Glcci1 | Glucocorticoid induced transcript 1 | #5 (m > f > flut) |
| Lipid binding | Prkca | Protein kinase c, alpha | #5 (m > f > flut) |
| Lipid binding | Ncam1 | Neural cell adhesion molecule 1 | #5 (m > f > flut) |
| Lipid binding | Gpc6 | Glypican 6 | #2 (m > flut > f) |
| Steroid hormone receptor activity | Nr6a1 | Nuclear receptor subfamily 6, group a, member 1 | #2 (m > flut > f) |
| Steroid hormone receptor activity | Nr2c2 | Nuclear receptor subfamily 2, group c, member 2 | #2 (m > flut > f) |
| Cellular lipid metabolic process | Sgpp1 | Sphingosine-1-phosphate phosphatase 1 | #2 (m > flut > f) |
| Cellular lipid metabolic process | Pbx1 | Pre b-cell leukemia transcription factor 1 | #5 (m > f > flut) |
| Cellular lipid metabolic process | Hsd17b12 | Hydroxysteroid (17-beta) dehydrogenase 12 | #2 (m > flut > f) |
| Cellular lipid metabolic process | Hadhb | Hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl-coenzyme A thiolase/enoyl-coenzyme A hydratase (trifunctional protein), beta subunit | #2 (m > flut > f) |
| Cellular lipid metabolic process | Ggtla1 | Gamma-glutamyltransferase-like activity 1 | #3 (flut > f > m) |
| Respiratory gaseous exchange | Pbx3 | Pre b-cell leukemia transcription factor 3 | #2 (m > flut > f) |
| Respiratory tube development | Nfib | Nuclear factor i/b | #2 (m > flut > f) |
| Respiratory tube development | Foxp1 | Forkhead box P1 | #5 (m > f > flut) |
| Embryonic development | Kif1b | Kinesin family member 1b | #2 (m > flut > f) |
| Embryonic development | Ext1 | Exostoses (multiple) 1 | #2 (m > flut > f) |
|
|
|||
| Lipid binding | Rock1 | Rho-associated coiled-coil forming kinase 1 | #5 (m > f > flut) |
| Lipid binding | Nr5a2 | Nuclear receptor subfamily 5, group a, member 2 | #5 (m > f > flut) |
| Steroid hormone receptor activity | Nr5a2 | Nuclear receptor subfamily 5, group a, member 2 | #5 (m > f > flut) |
| Cellular lipid metabolic process | Pip5k3 | Phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, type III | #4 (f > flut > m) |
| Cellular lipid metabolic process | Pbx1 | Pre b-cell leukemia transcription factor 1 | #4 (f > flut > m) |
| Cellular lipid metabolic process | Nr5a2 | Nuclear receptor subfamily 5, group a, member 2 | #5 (m > f > flut) |
| Cellular lipid metabolic process | Idi1 | Isopentenyl-diphosphate delta isomerase | #2 (m > flut > f) |
| Cellular lipid metabolic process | Elovl6 | Elovl family member 6, elongation of long chain fatty acids (yeast) | #2 (m > flut > f) |
| Cellular lipid metabolic process | Dhcr24 | 24-dehydrocholesterol reductase | #2 (m > flut > f) |
| Cellular lipid metabolic process | Crls1 | Cardiolipin synthase 1 | #5 (m > f > flut) |
| Lipid transport | Osbpl9 | Oxysterol binding protein-like 9 | #4 (f > flut > m) |
| Respiratory gaseous exchange | Fut8 | Fucosyltransferase 8 | #4 (f > flut > m) |
| Respiratory tube development | Gli1 | Gli-kruppel family member gli1 | #2 (m > flut > f) |
1Genes are situated among their corresponding expression patterns presented in Table 1. Flut: flutamide treated males. m: males. f: females.
In addition to the genes presenting both sex- and flutamide-driven modulations, some others presented either a sex difference or a transcriptional modulation by flutamide treatment at GD17 or GD18. Many of these genes are related to androgen receptor signalling and are more specifically known as co-regulators in the formation of AR complex (Fig.
Several other genes presenting either a sex difference or transcriptional modulation by flutamide treatment at GD17 or GD18 are known to be involved in pulmonary development signalling pathways or in surfactant synthesis or regulation (Table
Genes associated with pulmonary development or surfactant that are modulated by sex and/or antiandrogen treatment
|
|
|
|
|
|
|
|||
| Shh signaling | Gli1 | GLI-Kruppel family member GLI1 | 17 m>17 f; 18 m>18 f |
| Shh signaling | Gli3 | GLI-Kruppel family member GLI3 | 17 m>17 f; 18 m>18 f |
| FGF signaling | Fgf10 | Fibroblast growth factor 10 | 17 m>17 f |
| TGF-β Signaling | Tgfbr3 | Transforming growth factor, beta re ceptor III | 17 m>17 f |
| TGF-β Signaling | Tsc22d1 | TSC22 domain family, member 1 | 17 m>17 f |
| TGF-β Signaling | Tgfb2 | Transforming growth factor, beta 2 | 17 flut>17 m |
| BMP signaling | Bmpr2 | Bone morphogenic protein receptor, type II | 17 m>17 f; 18 m>18 flut |
| BMP signaling | Gdf10 | Growth differentiation factor 10 | 17 m>17 flut |
| BMP signaling | Gdf15 | Growth differentiation factor 15 | 17 flut>17 m |
| Wnt signaling | Gsk3b | Glycogen synthase kinase 3 beta | 17 m>17 f |
| Wnt signaling | Ctnna1 | Catenin (cadherin associated protein), alpha 1 | 17 m>17 f |
| Wnt signaling | Tcf4 | Transcription factor 4 | 17 m>17 f |
| Wnt signaling | Crebbp | CREB binding protein | 17 m>17 f |
|
|
|||
| Phosphatidyl cholin synthesis | Lpin2 | Lipin 2 | 17 m>17 f; 18 m>18 f |
| Phosphatidyl cholin synthesis | Chka | Choline kinase alpha | 17 m>17 f; 17 m>17 flut; 18 m>18 f; 18 m>18 flut |
| Phosphatidyl cholin synthesis | Cds2 | CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 | 18 flut>18 m |
| Phosphatidyl cholin synthesis | Aytl2 (Lpcat1) | Lysophosphatidylcholine acyltransferase 1 | 17 flut>17 m |
| Sphingolipids synthesis | Mgll | Monoglyceride lipase | 17 f>17 m |
| Sphingolipids synthesis | Aldh9a1 | Aldehyde dehydrogenase 9, subfamily A1 | 17 f>17 m |
| Sphingolipids synthesis | Pnliprp2 | Pancreatic lipase-related protein 2 | 17 f>17 m |
| Sphingolipids synthesis | Sgpp1 | Sphingosine-1-phosphate phosphatase 1 | 17 f>17 m |
| Sphingolipids synthesis | Dusp11 | Dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) | 17 f>17 m |
| Sphingolipids synthesis | Crls1 | Cardiolipin synthase 1 | 17 f>17 m; 18 m>18 f |
| Sphingolipids synthesis | Gba | Glucosidase, beta, acid | 17 f>17 m |
| Surfactant proteins | Sftpa1 | Surfactant associated protein A1 | 17 flut>17 m; 17 flut>17 f; 18 m>17 m; 18 f>17 f |
| Surfactant proteins | Sftpb | Surfactant associated protein B | 17 flut>17 f; 18 m>17 m; 18 f>17 f |
| Surfactant proteins | Sftpc | Surfactant associated protein C | 17 flut>17 f; 18 m>17 m; 18 f>17 f; 18 m>18 flut |
| Surfactant proteins | Sftpd | Surfactant associated protein D | 18 m>17 m; 18 f>17 f |
|
|
|||
| Miscellaneous regulators | Klf5 | Kruppel-like factor 5 | 17 flut>17 m; 17 flut>17 f |
| Miscellaneous regulators | Ltbp1 | Latent transforming growth factor beta binding protein 1 | 17 m>17 f |
| Miscellaneous regulators | Pten | Phosphatase and tensin homolog | 17 m>17 f; 17 m>17 flut |
| Miscellaneous regulators | Magi1 | Membrane associated guanylate kinase, WW and PDZ domain containing 1 | 17 m>17 f |
| Miscellaneous regulators | Ptges2 | Prostaglandin E synthase 2 | 17 f>17 m |
| IGF signaling | Igfbp2 | Insulin-like growth factor binding protein 2 | 17 m>17 flut |
| IGF signaling | Igfbp5 | Insulin-like growth factor binding protein 5 | 17 m>17 flut |
| IGF signaling | Igf1 | Insulin-like growth factor 1 | 17 m>17 flut |
| IGF signaling | Igfr2 (Fcgr2b) | Fc receptor, IgG, low affinity IIb | 17 m>17 flut |
1Shh: sonic hedgehog, FGF: fibroblast growth factor, TGF-β: transforming growth factor beta, BMP: bone morphogenetic protein, Wnt: wingless integration site, PC: phosphatidyl choline, IGF: insulin growth factor.
2Flut: flutamide treated males, m: males, f: females.
We previously achieved a microarray analysis of the sex difference in fetal mouse lungs at GD15.5, GD16.5, and GD17.5 by using overnight mating [
The AR, which mediates androgen effects, is a nuclear transcription factor that binds to androgen-responsive elements as well as to co-activators and general transcription factors to control transcription of androgen-regulated genes [
During embryonic and pseudoglandular stages of lung development, sonic hedgehog (Shh) plays an important positive role. Indeed, lack of Shh signalling leads to severe pulmonary hypoplasia [
Some of the signalling components of pulmonary epithelial-mesenchymal interaction, essential for branching morphogenesis, are also more expressed in male than in female lungs, such as Fgf10 and Bmpr2 genes. Members of the fibroblast growth factor (FGF) family and in particular Fgf10 are potent chemotactic signalling molecules. Fgf10 elicits lung budding and branching morphogenesis [
Contrary to Fgf10 and Gli which are expressed in the mesenchyme, Bmp proteins (bone morphogenetic proteins) are expressed in the adjacent pulmonary epithelium. Bmps constitute the largest group of cytokines belonging to the TGF-β superfamily. Originally, they were identified as molecules regulating growth and differentiation of bone and cartilage. However, they also control growth, differentiation, and apoptosis in a diverse number of cell lines, including mesenchymal and epithelial cells, regulating embryogenesis and contributing to the maintenance and repair of adult tissues [
Other signalling proteins that regulate cell-cell interactions in many embryonic tissues belong to the Wnt (wingless-related) family. Wnts signal through multiple pathways, the most well-characterized being the canonical β-catenin/TCF pathway [
Five decades ago, it was already suggested that surfactant deficiency could cause hyaline membrane disease, currently called RDS. This disease of prematurely born infants is due to a lack of surfactant [
The surfactant proteins play crucial roles in the structure, function, and metabolism of surfactant. Four proteins enter in the composition of surfactant: Sftpa1, Sftpb, Sftpc, and Sftpd (also known as SP-A, SP-B, SP-C, and SP-D, respectively). According to our microarray results, the expression of the four surfactant protein genes increases over time in both male and female lungs, but does not show any significant sexual difference. Compared to male lungs, Sftpa1 expression was augmented in flutamide-treated males at GD17, while Sftpc mRNA levels were higher in males than in flutamide-treated males at GD18. Thus, our results cannot totally exclude the participation of androgens in the control of expression of these genes.
Some factors involved in lung morphogenesis are also involved in surfactant synthesis regulation. Kruppel-like factor 5 (Klf5) gene is involved in lamellar body formation, in the stability of DPPC and Sftpb levels in late gestation in mouse, and in lung maturation during the saccular stage of development [
Several members of insulin-like growth factor (IGF) family show flutamide-responsive expression. Indeed, genes coding for Igf binding proteins Igfbp2 and Igfbp5, as well as Igf1 and Igf receptor 2 (Igfr2) are more highly expressed in males when compared to flutamide-treated males. Among them, only the Igfr2 gene exhibits a sexual difference, being more highly expressed in males than in females. Another factor involved in surfactant regulation is prostaglangin E2 (Ptges2), which increases surfactant secretion in rat [
While early lung development is characterized by cell proliferation, late lung development is predominantly governed by cell differentiation processes during which proliferation is markedly reduced. The fact that male-GD17 lungs showed increased expression of some proliferative signals, like Fgf10, compared to female lungs put forward the thesis that male lungs are not yet fully engaged in the differentiation processes at GD17, but Tgfbr3 receptor expression suggests a tight control of cell proliferation. Even if TGF-β is a negative regulator of airway branching morphogenesis in early lung development, its signalling is active in several tissue types in the lung during normal late development [
Furthermore, many genes involved in lipid processing have been shown to be expressed with sexual dimorphism. Some genes involved in this process have a sexual difference at GD17 or GD18, and some show flutamide-sensitive modulation. Even though it is difficult to confirm that the phospholipids synthesis is delayed for one sex, it is well known that the male disadvantage in lung maturation is mediated by androgens and that these steroids lead to a reduction in choline incorporation into DPPC in vitro [
Generally, the male lung seems more "transcriptionally active" than the female lung at GD17. Indeed, the majority of genes differentially expressed between sexes are more highly expressed in males. This transcriptional activity difference suggests that some processes are delayed in male lungs compared to females. Accordingly, there is an obvious decrease in transcriptional activity in male lungs between GD17 and GD18 while, during the same period, the number of genes showing a higher expression level in female lungs remain stable.
Taken together, our results are compatible with a delay in expression of pathways related to late development for one sex, with female lungs already more advanced in their maturation process, and male lungs showing an important transcriptional activity for pathways related to proliferation. By identifying several genes that are modulated according to sex and/or by antiandrogen in male fetal lungs, this study provides a significant number of candidate genes under the control of androgens that are likely to be involved in the delay in lung maturation observed in males. Further investigations of these candidates will be helpful in the understanding of this sexual dimorphism and have the potential to give valuable insights relevant to the prevention and treatment of short- and long-term consequences resulting from a wide range of pathologies associated with lung immaturity, such as RDS and BPD.
The authors declare that they have no competing interests.
EB carried out the microarray data analysis and drafted the manuscript. TS carried out mice matings, injection protocol, tissue harvesting, sample preparation for microarray experiments and Q-PCR, and also participated to design study and to draft the manuscript. MC participated in mice matings and injection protocol. GC carried out Q-PCR confirmations. PRP participated in the conception and design of the study. BP participated in the conception and design of the study. YT conceived and coordinated the study. All authors read and approved the final manuscript.
This work was supported by grants to YT from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). TS was supported by The Wyeth Pharmaceuticals & CIHR/Rx&D Research Fellowship Program and EB was supported by the Strategic Training Initiative in Research in Reproductive Health Sciences (STIRRHS).